Barclays analyst Stephanie Davis raised the firm’s price target on Quest Diagnostics (DGX) to $168 from $154 and keeps an Equal Weight rating on the shares. The company reported a solid Q3 print marked by a headline beat, intact earnings guidance despite hurricane headwinds, and positive early color on fiscal 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics upgraded to Outperform from Neutral at Baird
- Early notable gainers among liquid option names on October 22nd
- Morning Movers: 3M gains and GE Aerospace falls following third quarter results
- Quest Diagnostics narrows FY24 adjusted EPS view to $8.85-$8.95 from $8.80-$9.00
- Quest Diagnostics reports Q3 adjusted EPS $2.30, consensus $2.26